首页> 美国卫生研究院文献>Journal of Veterinary Science >Guideline on safety evaluation of cell-based medicinal products for animal use
【2h】

Guideline on safety evaluation of cell-based medicinal products for animal use

机译:动物用基于细胞的药用产品安全性评估指南

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

With the increased use of cell therapy in the veterinary sector, there is a growing demand for the development of cell-based medicinal products and the determination of their safety. Currently, the Korean Animal and Plant Quarantine Agency has established a guideline for evaluating the safety of cell-based medicinal products for animal use. The guideline includes items related to definition, classification, management, manufacturing procedure and quality control (standard and test method), stability testing, toxicity testing, pharmacological testing, and performance of clinical trials. In addition, testing protocols related to safety assessment of animal cell-based products such as chromosome karyotyping, tumorigenicity testing, confirmatory testing of biodistribution and kinetics, and target animal safety testing are described in detail. Moreover, because cell-based medicinal products are novel therapies, deviations from traditional designs may be justified in order to obtain relevant safety information on the treatment. Additionally, this guideline can be amended on the basis of new scientific findings.
机译:随着在兽医领域中细胞疗法的越来越多的使用,对基于细胞的药物产品的开发及其安全性确定的需求不断增长。目前,韩国动植物检疫局已经建立了评估用于动物的基于细胞的药品安全性的指南。该指南包括与定义,分类,管理,制造程序和质量控制(标准和测试方法),稳定性测试,毒性测试,药理测试以及临床试验性能有关的项目。此外,还详细介绍了与基于动物细胞的产品的安全性评估有关的测试方案,例如染色体核型分析,致瘤性测试,生物分布和动力学的确认性测试以及目标动物的安全性测试。此外,由于基于细胞的药物是新颖的疗法,因此有理由偏离传统设计以获取有关治疗的相关安全信息。此外,可以根据新的科学发现对本指南进行修订。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号